{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:38:38Z","timestamp":1762177118190,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Glecaprevir (an NS3\/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in NS3 or NS5A detected in samples from HCV genotype 1-infected patients receiving 3-day monotherapy of glecaprevir or pibrentasvir, respectively. None of the NS3 polymorphisms detected in the 47 baseline samples collected prior to glecaprevir monotherapy conferred reduced susceptibility to glecaprevir. The NS3 A156T substitution, which conferred resistance to glecaprevir but had low replication efficiency, emerged in one genotype 1a-infected patient among the 35 patients with available post-baseline sequence data. Baseline NS5A polymorphisms were detected in 12 of 40 patients prior to pibrentasvir monotherapy; most polymorphisms were single-position NS5A amino acid substitutions that did not confer resistance to pibrentasvir. Among the 19 patients with available post-baseline NS5A sequence data, 3 had treatment-emergent NS5A substitutions during pibrentasvir monotherapy. All treatment-emergent NS5A substitutions were linked multiple-position, almost exclusively double-position, substitutions that conferred resistance to pibrentasvir. Replicons engineered with these double-position substitutions had low replication efficiency. In conclusion, resistance-conferring substitutions emerged in a small number of genotype 1-infected patients during glecaprevir or pibrentasvir monotherapy; unlike other NS5A inhibitors, pibrentasvir did not select single-position NS5A substitutions during monotherapy.<\/jats:p>","DOI":"10.3390\/v10090462","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T12:19:06Z","timestamp":1535458746000},"page":"462","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection"],"prefix":"10.3390","volume":"10","author":[{"given":"Teresa I.","family":"Ng","sequence":"first","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami","family":"Pilot-Matias","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Tripathi","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretja","family":"Schnell","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Reisch","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Beyer","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Dekhtyar","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Irvin","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangjun","family":"Lu","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Asatryan","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Campbell","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty","family":"Yao","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lovell","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Mensa","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Lawitz","sequence":"additional","affiliation":[{"name":"Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX 78215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-6886","authenticated-orcid":false,"given":"Jens","family":"Kort","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Collins","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,8,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2017). Global Hepatitis Report, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1021\/ml500070q","article-title":"The HCV revolution did not happen overnight","volume":"5","author":"Kwong","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-acting antivirals for the treatment of hepatitis C virus infection: Optimizing current IFN-free treatment and future perspectives","volume":"36","author":"Asselah","year":"2016","journal-title":"Liver Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review","volume":"166","author":"Nelson","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","article-title":"Differential efficacy of protease inhibitors against HCV genotypes 2a; 3a; 5a; and 6a NS3\/4A protease recombinant viruses","volume":"141","author":"Gottwein","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1\u20137 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.coviro.2013.06.014","article-title":"Antiviral activity and resistance of HCV NS5A replication complex inhibitors","volume":"3","author":"Gao","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_12","first-page":"1393A","article-title":"Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection","volume":"62","author":"Jacobson","year":"2015","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","article-title":"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir","volume":"58","author":"McPhee","year":"2013","journal-title":"Hepatology"},{"key":"ref_14","unstructured":"Janssen Products (2013). Olysio (Simeprevir). Highlights of Prescribing Information, Janssen Therapeutics."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: State of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Romano, K.P., Ali, A., Aydin, C., Soumana, D., Ozen, A., Deveau, L.M., Silver, C., Cao, H., Newton, A., and Petropoulos, C.J. (2012). The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002832"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e02558-16","DOI":"10.1128\/AAC.02558-16","article-title":"In Vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e01620-17","DOI":"10.1128\/AAC.01620-17","article-title":"In Vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.02264-15","article-title":"Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In Vitro and In Vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Tripathi","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In Vitro and In Vivo antiviral activity and resistance profile of ombitasvir; an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/jmv.23399","article-title":"Distribution of hepatitis C virus genotypes in a diverse US integrated health care population","volume":"84","author":"Manos","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a; 1b; and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/hep.29693","article-title":"Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives","volume":"67","author":"Harrington","year":"2018","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","article-title":"NS5A inhibitors in the treatment of hepatitis C","volume":"59","author":"Pawlotsky","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816); a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3851\/IMP2729","article-title":"Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b","volume":"19","author":"McPhee","year":"2014","journal-title":"Antivir. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","article-title":"Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir","volume":"66","author":"Wyles","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In Vitro and In Vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11124","DOI":"10.1128\/JVI.01217-10","article-title":"Tracking the evolution of multiple In Vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing","volume":"84","author":"Verbinnen","year":"2010","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.1016\/S0168-8278(12)61220-3","article-title":"Evaluation of NS3 amino acid variants in a phase 1b study of genotype 1 (GT1) and GT3 infected patients with the HCV protease inhibitor; MK-5172","volume":"56","author":"Strizki","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lawitz, E., Yang, J.C., Stamm, L.M., Taylor, J.G., Cheng, G., Brainard, D.M., Miller, M.D., Mo, H., and Dvory-Sobol, H. (2017). Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir; a novel pangenotypic NS3\/4A protease inhibitor. Antivir. Ther.","DOI":"10.3851\/IMP3202"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir; velpatasvir; and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","article-title":"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection","volume":"59","author":"Howe","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","unstructured":"(2018, May 01). Center for Drug Evaluation and Research, Zepatier Microbiology\/Virology Review, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208261Orig1s000MicroR.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep4.1050","article-title":"Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review","volume":"1","author":"Bartlett","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cld.631","article-title":"Resistance testing: Interpretation and incorporation into HCV treatment algorithms","volume":"9","author":"Feld","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"01249-18","DOI":"10.1016\/S0168-8278(17)31399-5","article-title":"Pooled resistance analysis in HCV genotype 1\u20136-infected patients treated with glecaprevir\/pibrentasvir in phase 2 and 3 clinical trials","volume":"66","author":"Krishnan","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/9\/462\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:21:39Z","timestamp":1760196099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/9\/462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,28]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["v10090462"],"URL":"https:\/\/doi.org\/10.3390\/v10090462","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2018,8,28]]}}}